142 related articles for article (PubMed ID: 34387605)
1. Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
Hijab A; Taha T; Charas T; Bar-Sela G; Stein P; Agbarya A
Anticancer Drugs; 2022 Jan; 33(1):e747-e751. PubMed ID: 34387605
[TBL] [Abstract][Full Text] [Related]
2. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
3. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Garnick MB
BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
[No Abstract] [Full Text] [Related]
6. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
Beebe-Dimmer JL; Ruterbusch JJ; Bylsma LC; Gillezeau C; Fryzek J; Schultz NM; Flanders SC; Barlev A; Heath E; Quek RGW
Adv Ther; 2018 Sep; 35(9):1438-1451. PubMed ID: 29946798
[TBL] [Abstract][Full Text] [Related]
7. Bicalutamide with radiotherapy for prostate cancer.
Brower V
Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
[No Abstract] [Full Text] [Related]
8. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
9. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Yoshida T
Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
[No Abstract] [Full Text] [Related]
10. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
[TBL] [Abstract][Full Text] [Related]
11. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
12. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
Rapkiewicz A; Gorokhovsky R; Farcon E; Das K
Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888
[TBL] [Abstract][Full Text] [Related]
13. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
14. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
Parker C; Clarke N; Logue J; Payne H; Catton C; Kynaston H; Murphy C; Morgan R; Morash C; Parulekar W; Parmar M; Savage C; Stansfeld J; Sydes M;
Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):167-71. PubMed ID: 17359901
[No Abstract] [Full Text] [Related]
15. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
18. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
[TBL] [Abstract][Full Text] [Related]
19. [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
Barbón JJ; González-Tuero J; Gay LL; Pérez-García FJ; Sampedro A
Arch Soc Esp Oftalmol; 2007 Nov; 82(11):715-7. PubMed ID: 17979041
[TBL] [Abstract][Full Text] [Related]
20. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
[Next] [New Search]
